PRESCIENT THERAPEUTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.046 AUD | 0.00% |
|
-11.54% | -25.81% |
| Mar. 25 | Transcript : Prescient Therapeutics Limited - Special Call | |
| Feb. 23 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Presenter SpeechPatrick Nelson (Attendees)Good afternoon, and welcome to this focus event for ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.
Calendar
2024-08-25
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.81% | 24.5M | |
| +22.81% | 47.9B | |
| +46.56% | 41.42B | |
| -1.88% | 40.7B | |
| -6.20% | 28.92B | |
| +11.33% | 25.55B | |
| -21.00% | 19.27B | |
| -1.43% | 12.15B | |
| +30.73% | 12.14B | |
| -0.48% | 11.99B |
- Stock Market
- Equities
- PTX Stock
- News Prescient Therapeutics Limited
- Transcript : Prescient Therapeutics Limited - Special Call